Stock Scorecard
Stock Summary for Compass Therapeutics Inc (CMPX) - $6.40 as of 2/2/2026 10:24:47 AM EST
Total Score
7 out of 30
Safety Score
38 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CMPX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CMPX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CMPX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CMPX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CMPX (38 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CMPX
Financial Details for CMPX
Company Overview |
|
|---|---|
| Ticker | CMPX |
| Company Name | Compass Therapeutics Inc |
| Country | USA |
| Description | Compass Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company headquartered in Boston, dedicated to developing advanced antibody-based therapies for cancer and other severe diseases. Leveraging a proprietary technology platform, the firm is advancing its promising drug candidates through rigorous clinical trials, aiming to deliver targeted interventions that enhance patient outcomes significantly. With a robust pipeline poised to make a substantial impact in oncology, Compass presents a compelling investment opportunity for institutional investors looking to capitalize on the evolving landscape of cancer therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/26/2026 |
Stock Price History |
|
| Last Day Price | 6.40 |
| Price 4 Years Ago | 5.03 |
| Last Day Price Updated | 2/2/2026 10:24:47 AM EST |
| Last Day Volume | 2,839,040 |
| Average Daily Volume | 2,431,286 |
| 52-Week High | 6.49 |
| 52-Week Low | 1.33 |
| Last Price to 52 Week Low | 381.20% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.68 |
| Sector PE | 188.49 |
| 5-Year Average PE | -8.00 |
| Free Cash Flow Ratio | 24.62 |
| Industry Free Cash Flow Ratio | 12.86 |
| Sector Free Cash Flow Ratio | 30.14 |
| Current Ratio Most Recent Quarter | 17.82 |
| Total Cash Per Share | 0.26 |
| Book Value Per Share Most Recent Quarter | 1.18 |
| Price to Book Ratio | 5.41 |
| Industry Price to Book Ratio | 64.54 |
| Sector Price to Book Ratio | 57.14 |
| Price to Sales Ratio Twelve Trailing Months | 439.25 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.05 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.56 |
| Analyst Buy Ratings | 11 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 177,862,000 |
| Market Capitalization | 1,138,316,800 |
| Institutional Ownership | 83.83% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -16.19% |
| Reported EPS 12 Trailing Months | -0.45 |
| Reported EPS Past Year | -0.34 |
| Reported EPS Prior Year | -0.37 |
| Net Income Twelve Trailing Months | -65,806,000 |
| Net Income Past Year | -49,375,000 |
| Net Income Prior Year | -42,494,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 46,212,000 |
| Total Cash Past Year | 43,483,000 |
| Total Cash Prior Year | 24,228,000 |
| Net Cash Position Most Recent Quarter | 46,212,000 |
| Net Cash Position Past Year | 43,483,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 125,232,000 |
| Total Stockholder Equity Prior Year | 148,538,000 |
| Total Stockholder Equity Most Recent Quarter | 209,613,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -45,076,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.25 |
| Free Cash Flow Past Year | -44,899,000 |
| Free Cash Flow Prior Year | -40,648,000 |
Options |
|
| Put/Call Ratio | 0.03 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.28 |
| MACD Signal | 0.22 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.26 |
| RSI | 58.72 |
| 50-Day SMA | 3.39 |
| 150-Day SMA | 2.47 |
| 200-Day SMA | 2.66 |
System |
|
| Modified | 1/30/2026 8:14:23 PM EST |